×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
上海药物研究所 [27]
合肥物质科学研究院 [11]
中国医学科学院 北京... [4]
上海生物化学与细胞生... [3]
北京大学 [2]
金属研究所 [2]
更多...
内容类型
期刊论文 [55]
发表日期
2024 [1]
2021 [5]
2020 [4]
2019 [2]
2018 [7]
2017 [20]
更多...
学科主题
Pharmacolo... [3]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共55条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers
期刊论文
CANCER LETTERS, 2024, 卷号: 582, 页码: 15
作者:
Lu, Xuxiu
;
Yu, Rilei
;
Li, Zhen
;
Yang, Mengke
;
Dai, Jiajia
收藏
  |  
浏览/下载:4/0
  |  
提交时间:2024/04/07
Acquired resistance
Cancer
NSCLC
JC-010a
SHP2
LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo
期刊论文
CANCER SCIENCE, 2021, 页码: 12
作者:
Liu, Yingqiang
;
Lai, Mengzhen
;
Li, Shan
;
Wang, Yanan
;
Feng, Fang
收藏
  |  
浏览/下载:62/0
  |  
提交时间:2022/01/18
C797S
epidermal growth factor receptor
fourth-generation EGFR TKI
non-small cell lung cancer
osimertinib resistance
Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans
期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10
作者:
Meng, Jian
;
Zhang, Hua
;
Bao, Jing-jing
;
Chen, Zhen-dong
;
Liu, Xiao-yun
收藏
  |  
浏览/下载:69/0
  |  
提交时间:2021/06/11
metabolism
mass balance
distribution
covalent binding
furmonertinib
Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans
期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10
作者:
Meng, Jian
;
Zhang, Hua
;
Bao, Jing-jing
;
Chen, Zhen-dong
;
Liu, Xiao-yun
收藏
  |  
浏览/下载:70/0
  |  
提交时间:2021/06/11
metabolism
mass balance
distribution
covalent binding
furmonertinib
Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells
期刊论文
THORACIC CANCER, 2021, 页码: 9
作者:
Zhang, Mi
;
Quan, Haitian
;
Fu, Li
;
Li, Yun
;
Fu, Haoyu
收藏
  |  
浏览/下载:18/0
  |  
提交时间:2021/05/24
EGFR‐
mutant non‐
small cell lung cancer
famitinib
HS‐
10296
multi‐
targeted tyrosine kinase inhibitor
third‐
generation EGFR inhibitor
Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers
期刊论文
INVESTIGATIONAL NEW DRUGS, 2021, 页码: 8
作者:
Zhu, Yun-ting
;
Zhang, Yi-fan
;
Jiang, Jin-fang
;
Yang, Yong
;
Guo, Li-xia
收藏
  |  
浏览/下载:27/0
  |  
提交时间:2021/05/24
Alflutinib
Rifampicin
CYP3A4
AST5902
Drug-drug interaction
Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026
作者:
Shi, Yuankai
;
Zhang, Shucai
;
Hu, Xingsheng
;
Feng, Jifeng
;
Ma, Zhiyong
收藏
  |  
浏览/下载:38/0
  |  
提交时间:2020/12/24
Alflutinib
NSCLC
EGFR T790M mutation
Efficacy
Safety
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
期刊论文
MOLECULAR CANCER, 2020, 卷号: 19, 期号: 1, 页码: 15
作者:
Zhang, Tao
;
Qu, Rong
;
Chan, Shingpan
;
Lai, Mengzhen
;
Tong, Linjiang
收藏
  |  
浏览/下载:40/0
  |  
提交时间:2020/07/01
Non-small cell lung cancer (NSCLC)
EGFR T790M
Small-molecule inhibitor
Drug resistance
Ack1
Design and synthesis of selective degraders of EGFR(L858R/T790M) mutant
期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 卷号: 192, 页码: 14
作者:
Zhang, Xin
;
Xu, Fang
;
Tong, Linjiang
;
Zhang, Tao
;
Xie, Hua
收藏
  |  
浏览/下载:80/0
  |  
提交时间:2020/07/01
Epidermal growth factor receptor (EGFR)
Resistance
Proteolysis targeting chimera (PROTAC)
Protein degradation
Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer
期刊论文
ACTA PHARMACOLOGICA SINICA, 2020, 页码: 11
作者:
Liu, Xiao-yun
;
Guo, Zi-tao
;
Chen, Zhen-dong
;
Zhang, Yi-fan
;
Zhou, Jia-lan
收藏
  |  
浏览/下载:76/0
  |  
提交时间:2020/07/01
alflutinib
AST5902
metabolism
enzyme induction
drug-drug interaction
©版权所有 ©2017 CSpace - Powered by
CSpace